Levofloxacin Prophylaxis Versus no Prophylaxis in Acute Myeloid Leukemia During Post-Induction Aplasia: a Single Center Study
暂无分享,去创建一个
F. D. De Rosa | G. Ciccone | R. Rosato | A. Busca | R. Freilone | M. Cerrano | S. Corcione | E. Audisio | V. Giai | Chiara Frairia | C. Dellacasa | S. Aydin | I. Urbino | S. D'ardia | Carolina Secreto | S. D’ardia
[1] D. Buchheidt,et al. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) , 2020, Annals of Hematology.
[2] M. Boccadoro,et al. FLAI induction regimen in elderly patients with acute myeloid leukemia , 2019, Leukemia & lymphoma.
[3] M. Chayakulkeeree,et al. Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis , 2019, Hematology.
[4] C. Flowers,et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Pagano,et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria , 2018, Annals of Hematology.
[6] P. Bruzzi,et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. , 2018, The Journal of infection.
[7] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[8] R. Bellomo,et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.
[9] M. Aapro,et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Adil Rafiq Rather,et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .
[11] H. Rohde,et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. , 2014, The Journal of antimicrobial chemotherapy.
[12] R. Evans. European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[13] F. D. De Rosa,et al. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis , 2013, BMC Infectious Diseases.
[14] M. Lichtman. A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. , 2013, Blood cells, molecules & diseases.
[15] S. Berendse,et al. Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance , 2012, BMJ : British Medical Journal.
[16] L. Mileshkin,et al. Use of antibacterial prophylaxis for patients with neutropenia , 2011, Internal medicine journal.
[17] D. Warren,et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] L. Leibovici,et al. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients , 2007 .
[19] R. Foà,et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. , 2005, The New England journal of medicine.
[20] F. Cainelli,et al. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. , 2003, The Lancet. Oncology.
[21] B. Czepulkowski,et al. Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia , 1997, British journal of haematology.